Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (RXRX) is a clinical-stage biotechnology pioneer using machine learning and automated experiments to transform drug discovery. This page serves as the definitive source for all official company announcements and verified news coverage.
Investors and industry professionals will find timely updates including clinical trial developments, strategic partnerships, and financial results. Our curated collection features press releases on therapeutic advancements, regulatory milestones, and technology innovations from Recursion's proprietary platform.
Key content categories include quarterly earnings reports, research collaborations, pipeline updates, and executive leadership announcements. All materials are sourced directly from company filings and reputable financial news outlets to ensure accuracy.
Bookmark this page for streamlined access to RXRX's latest progress in decoding complex diseases through computational biology. Check regularly for real-time updates on one of biotech's most technologically advanced drug discovery efforts.
Recursion (NASDAQ: RXRX) and Enamine have announced a collaboration to create AI-enabled targeted compound libraries for drug discovery. The partnership combines Recursion's AI/ML platform (Recursion OS) with Enamine's REAL Space, the world's largest make-on-demand small molecule collection.
The collaboration has resulted in 10 enriched screening libraries comprising over 15,000 newly synthesized compounds, designed to accelerate drug discovery against 100 key clinical targets in challenging biological areas. By leveraging Recursion's AI technology to predict small molecule compatibility with protein targets, the partnership enables the creation of focused libraries that outperform traditional high-throughput screening collections.
As part of the research collaboration, Recursion gained access to tens of thousands of compounds for its internal discovery needs, while helping develop libraries of broad commercial interest. The curated libraries are now available through Enamine's website for customer hit-finding campaigns.
Recursion (RXRX) has initiated dosing in the Phase 1 EXCELERIZE clinical study of REC-3565, a selective MALT1 inhibitor designed for treating relapsed or refractory B-cell lymphomas. The compound, developed using Recursion's AI-powered platform, showed promising preclinical results with durable tumor regressions both as monotherapy and combined with BTK inhibitors.
The study consists of two parts: Part A will evaluate monotherapy dosing, while Part B will assess combination regimens. REC-3565's allosteric design aims to enhance potency and selectivity while potentially reducing liver toxicity risks associated with UGT1A1 inhibition, a common side effect in other MALT1 inhibitors.
Notably, the development timeline was accelerated, with the lead candidate delivered in just 15 months using the Recursion OS platform, which combines physics-based modeling with molecular dynamics and hotspot analysis.
Recursion (RXRX), a clinical stage TechBio company focused on drug discovery, has announced its upcoming participation in the Needham 24th Annual Virtual Healthcare Conference scheduled for April 7, 2025.
Investors and interested parties can access the conference webcasts through the events section of Recursion's Investor Relations website at ir.recursion.com.
Recursion (NASDAQ: RXRX) has strengthened its Board of Directors with two significant appointments effective March 15th. Dr. Namandjé Bumpus, former FDA Principal Deputy Commissioner until December 2024, brings extensive experience in regulatory science and AI integration. Elaine Sun, current COO and CFO at Mammoth Biosciences, contributes 30 years of life sciences and financial industry expertise.
Dr. Bumpus previously served as FDA's Chief Scientist and was instrumental in shaping the agency's strategic direction, particularly in AI regulatory science integration. She also held positions at Johns Hopkins University School of Medicine as an endowed professor and department chair.
Elaine Sun's experience includes leadership roles at Halozyme Therapeutics and SutroVax (now Vaxcyte), along with advisory roles in M&A and financing transactions exceeding $50 billion at Evercore Partners and Merrill Lynch. She currently serves on the boards of Dynavax Technologies and Asher Biotherapeutics.
Recursion (RXRX) reported its Q4 and FY2024 financial results, highlighting significant clinical and operational achievements. The company demonstrated promising safety and efficacy data for REC-617 in cancer treatment and REC-994 in cerebral cavernous malformations. Three new clinical studies were initiated across oncology, rare disease, and C. diff infection.
Key financial metrics for FY2024 include:
- Revenue: $58.8M (up from $44.6M in 2023)
- Cash position: $603.0M as of December 31, 2024
- Net loss: $463.7M (increased from $328.1M in 2023)
The company completed a strategic merger with Exscientia and delivered partnership milestones with Roche, Genentech, and Sanofi, generating $45M in cash inflows. Platform advancements include the launch of BioHive-2 supercomputer and development of new AI models. Cash runway is expected to extend into 2027.
Recursion (RXRX), a clinical stage TechBio company focused on drug discovery, has announced it will release its Q4 and full-year 2024 financial results on February 28, 2025, before market open. The company will host a live earnings call at 8:30 AM ET/6:30 AM MT/1:30 PM GMT on the same day.
The earnings call will be broadcast live through Recursion's social media channels including X (formerly Twitter), LinkedIn, and YouTube. Stakeholders, including investors and analysts, will have the opportunity to submit questions through a dedicated link.
Altitude Lab, a biotech accelerator founded by Recursion (NASDAQ: RXRX), has launched a pre-seed venture fund to support early-stage biotechnology startups affected by federal funding policy changes. The fund will provide $100,000–$250,000 in pre-seed investment capital, 12 months of lab space, and admission to Altitude Lab's accelerator program.
The initiative aims to bridge the gap created by recent policy shifts that have impacted approximately 1,500 health-related startups dependent on Small Business Innovation Research (SBIR) grants. The fund will be led by Recursion CEO Chris Gibson, alongside entrepreneur David Bearss and Altitude's executive director Chandana Haque.
Altitude Lab's startups have raised $154M from 2020 to 2024, representing over 50% of life science-focused early-stage capital in Utah. Eligible startups must have received an Impact Score of 20 or less in a recent SBIR submission.
Altitude Lab, founded by Recursion (NASDAQ: RXRX), announced that its incubating startups have raised $154 million in early-stage funding since 2020. The lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, CEO of Elnora AI, providing $150,000 in funding and support.
Key achievements include:
- 19 current startups and 12 alumni
- 70% of startups led by underrepresented founders
- 90% of participating startups have raised capital
Notable portfolio milestones include Peel Therapeutics completing Phase 1 trial and initiating Series A, Rebel Medicine receiving IND approval and starting Series A, Sethera appointing Moderna co-founder as advisory board chair, and Teiko launching a 25-marker spectral flow cytometry assay.
Recursion (RXRX) has reported positive 12-month data from its Phase 2 SYCAMORE trial of REC-994 for Cerebral Cavernous Malformations (CCM). The study met its primary endpoint of safety and tolerability, with no treatment-related discontinuations or Grade 3 adverse events.
Key findings for the 400mg dose include: 50% of patients showed reduction in total lesion volume versus 28% in placebo, with an absolute mean decrease of 457 mm³ compared to a 53 mm³ increase in placebo. Patients demonstrated trends toward improvement in modified Rankin scale (mRS) scores, particularly in those with brainstem lesions.
The most common adverse events included Covid-19, dizziness, headache, back pain, and constipation. The company plans to determine next steps through regulatory discussions and ongoing long-term extension study results.
Recursion (NASDAQ: RXRX) has received regulatory clearances for two key oncology drugs to advance to clinical trials. The UK MHRA cleared a Phase 1 trial for REC-3565, a MALT1 inhibitor targeting B-cell malignancies, with a potential addressable market of 41,000 relapsed/refractory patients with chronic lymphocytic leukemia and B-cell lymphomas in US+EU5 annually.
The FDA cleared an IND application for REC-4539, a reversible and CNS-penetrant LSD1 inhibitor for small-cell lung cancer, targeting approximately 45,000 extensive stage SCLC patients annually in US+EU5. REC-3565 is designed to reduce hyperbilirubinemia risk, while REC-4539 is the first reversible LSD1 inhibitor designed to penetrate the brain.
FAQ
What is the current stock price of Recursion Pharmaceuticals (RXRX)?
What is the market cap of Recursion Pharmaceuticals (RXRX)?
